Investigation of IL-17A Serum Levels in Patients with Nonmelanoma Skin Cancer.
Journal
Dermatology research and practice
ISSN: 1687-6105
Titre abrégé: Dermatol Res Pract
Pays: Egypt
ID NLM: 101312803
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
02
2021
accepted:
11
06
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
10
7
2021
Statut:
epublish
Résumé
Role of interleukin 17A (IL-17A) in carcinogenesis and cancer growth is controversial. Although some researches support its antitumor activity, some others suggest that it promotes the growth and development of different types of cancer including skin cancer by activation of STAT3. Although the function of the cytokines such as IL-17A has been extensively studied in various types of cancer, nonmelanoma skin cancer (NMSC) has not received much attention. Therefore, the present study was aimed to investigate the serum levels of IL-17A in NMSC patients. This cross-sectional study was performed on 60 patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) as well as 57 age-sex matched healthy individuals as control group. Measurement of IL-17A serum levels in both case and control groups was performed by a commercially reliable sandwich enzyme-linked immunosorbent assay (ELISA) kit. In this study, we observed that IL-17A serum levels in NMSC patients were significantly higher than the control group ( According to our results, it can be concluded that IL-17A may play a role in inducing the growth and progression of NMSC and it can be used as a therapeutic target in these patients in future.
Sections du résumé
BACKGROUND
BACKGROUND
Role of interleukin 17A (IL-17A) in carcinogenesis and cancer growth is controversial. Although some researches support its antitumor activity, some others suggest that it promotes the growth and development of different types of cancer including skin cancer by activation of STAT3. Although the function of the cytokines such as IL-17A has been extensively studied in various types of cancer, nonmelanoma skin cancer (NMSC) has not received much attention. Therefore, the present study was aimed to investigate the serum levels of IL-17A in NMSC patients.
METHODS
METHODS
This cross-sectional study was performed on 60 patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) as well as 57 age-sex matched healthy individuals as control group. Measurement of IL-17A serum levels in both case and control groups was performed by a commercially reliable sandwich enzyme-linked immunosorbent assay (ELISA) kit.
RESULTS
RESULTS
In this study, we observed that IL-17A serum levels in NMSC patients were significantly higher than the control group (
CONCLUSION
CONCLUSIONS
According to our results, it can be concluded that IL-17A may play a role in inducing the growth and progression of NMSC and it can be used as a therapeutic target in these patients in future.
Identifiants
pubmed: 34239554
doi: 10.1155/2021/5540163
pmc: PMC8233089
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5540163Informations de copyright
Copyright © 2021 Mehdi Ghahartars et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Immunology. 2010 Mar;129(3):311-21
pubmed: 20409152
J Immunol. 2006 May 1;176(9):5652-61
pubmed: 16622035
Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1686-95
pubmed: 20570907
J Allergy Clin Immunol. 2019 Feb;143(2):631-643
pubmed: 29935220
Prog Transplant. 2008 Dec;18(4):232-41; quiz 242
pubmed: 19186575
J Immunol. 1993 Jun 15;150(12):5445-56
pubmed: 8390535
Immunity. 2004 Oct;21(4):467-76
pubmed: 15485625
Gastroenterology. 2010 Jun;138(6):2101-2114.e5
pubmed: 20420949
Immunol Rev. 2012 Mar;246(1):379-400
pubmed: 22435567
Cancer Discov. 2011 Oct;1(5):430-41
pubmed: 22408746
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii100-3
pubmed: 23253923
EMBO J. 2012 Jan 18;31(2):301-16
pubmed: 22068056
Lancet. 2010 Feb 20;375(9715):673-85
pubmed: 20171403
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
J BUON. 2016 Sept-Oct;21(5):1137-1145
pubmed: 27837615
Nat Rev Drug Discov. 2012 Oct;11(10):763-76
pubmed: 23023676
Eur J Immunol. 2015 Mar;45(3):922-31
pubmed: 25487261
Acta Derm Venereol. 2011 Jan;91(1):24-30
pubmed: 21264452
Adv Cancer Res. 2016;130:257-91
pubmed: 27037755
Immunol Cell Biol. 2001 Dec;79(6):547-68
pubmed: 11903614
Nat Rev Immunol. 2007 Jan;7(1):41-51
pubmed: 17186030
Cancer Res. 2010 Dec 15;70(24):10112-20
pubmed: 21159633
Skin Pharmacol Physiol. 2018;31(2):59-73
pubmed: 29262420
PLoS One. 2012;7(2):e32126
pubmed: 22359662
N Engl J Med. 2015 Oct;373(14):1318-28
pubmed: 26422722
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Prostate. 2003 Aug 1;56(3):171-82
pubmed: 12772186
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Annu Rev Immunol. 2009;27:485-517
pubmed: 19132915
Free Radic Biol Med. 2010 Dec 1;49(11):1603-16
pubmed: 20840865
Int J Hyg Environ Health. 2010 Sep;213(5):359-68
pubmed: 20619731
Recent Pat Inflamm Allergy Drug Discov. 2009 Jan;3(1):73-80
pubmed: 19149749
Front Oncol. 2019 Jun 20;9:546
pubmed: 31281798
Cytokine Growth Factor Rev. 2010 Feb;21(1):11-9
pubmed: 20018552
Carcinogenesis. 1998 May;19(5):723-9
pubmed: 9635856
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Cancer Sci. 2019 Oct;110(10):3068-3078
pubmed: 31432577
Expert Opin Investig Drugs. 2010 Oct;19(10):1147-59
pubmed: 20836616